Treats insomnia. ANDA 204299, held by Novel Labs Inc. Zolpidem Tartrate.
As of Nov 16, 2026, ANDA 204299 (Zolpidem Tartrate), held by Novel Labs Inc, was first approved by FDA on Jun 3, 2015, with 2 approved supplements and 0 published complete response letters.
Zolpidem Tartrate is a GABA A agonist indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep Limitation of Use: Not indicated for the treatment of middle-of-the night awakening when the patient has fewer than 4 hours of bedtime remaining before the planned time of waking
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 3, 2015 | Original application | Approved | None posted |
| Zolpidem Tartrate1.75MG · tablet;sublingual | Zolpidem Tartrate | Rx |
| Zolpidem Tartrate3.5MG · tablet;sublingual | Zolpidem Tartrate | Rx |
| Nov 29, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 29, 2019 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jun 3, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters